Sclair Seth N, Little Ester, Levy Cynthia
Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
Banner University Medical Center, Phoenix, Arizona, USA.
Clin Transl Gastroenterol. 2015 Aug 27;6(8):e109. doi: 10.1038/ctg.2015.33.
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic, cholestatic diseases of the liver with common clinical manifestations. Early diagnosis and treatment of PBC slows progression and decreases the need for transplant. However, one-third of patients will progress regardless of treatment. Bilirubin <1.0 and alkaline phosphatase <2.0 x the upper limit of normal at 1 year after treatment appear to predict 10-year survival. Ursodeoxycholic acid (UDCA) is the recommended treatment for PBC, and recent studies with obeticholic acid showed promising results for UDCA non-responders. Unlike PBC, no therapy has been shown to alter the natural history of PSC. The recommended initial diagnostic test for PSC is magnetic resonance cholangiopancreatography, typically showing bile duct wall thickening, focal bile duct dilatation, and saccular dilatation of the intra- and/or extrahepatic bile ducts. Immunoglobulin 4-associated cholangitis must be excluded when considering the diagnosis of PSC, to allow for proper treatment, and monitoring of disease progression. In addition to the lack of therapy, PSC is a pre-malignant condition and close surveillance is indicated.
原发性胆汁性肝硬化(PBC)和原发性硬化性胆管炎(PSC)是具有共同临床表现的慢性胆汁淤积性肝病。PBC的早期诊断和治疗可减缓疾病进展并减少移植需求。然而,三分之一的患者无论治疗与否都会进展。治疗1年后胆红素<1.0且碱性磷酸酶<正常上限的2.0倍似乎可预测10年生存率。熊去氧胆酸(UDCA)是PBC的推荐治疗药物,最近关于奥贝胆酸的研究对UDCA无反应者显示出有希望的结果。与PBC不同,尚无治疗方法被证明可改变PSC的自然病程。PSC推荐的初始诊断检查是磁共振胰胆管造影,通常表现为胆管壁增厚、局灶性胆管扩张以及肝内和/或肝外胆管的囊状扩张。在考虑PSC诊断时必须排除免疫球蛋白4相关性胆管炎,以便进行适当治疗和监测疾病进展。除了缺乏有效治疗方法外,PSC还是一种癌前病变,需要密切监测。